Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hatch, Harkin Call For Withdrawal of NDI Draft Guidance

This article was originally published in The Tan Sheet

Executive Summary

Sens. Hatch and Harkin ask FDA to craft a new document to replace the current NDI notification draft guidance, recommending the agency “provide needed clarification” on what constitutes an NDI.

Advertisement

Related Content

Revised NDI Notification Draft Guidance Shrinks Divide Between FDA And Industry
CRN Asks FDA To Stop Enforcement Against Synthetic Botanicals
CRN Asks FDA To Stop Enforcement Against Synthetic Botanicals
FDA Revision Of NDI Draft Guidance Starts With Grandfathered List
FDA Revision Of NDI Draft Guidance Starts With Grandfathered List
Reps Threaten Legislation To Align NDI Guidance With DSHEA
Reps Threaten Legislation To Align NDI Guidance With DSHEA
McCain-Dorgan NDI Guidance, Steroid Provisions In Senate Food Safety Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS105497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel